Edwards Lifesciences Lifts 2026 Constant-Currency Sales-Growth Outlook to About 11.5%
Photo: TokenPost
After third-quarter sales rose 11.2% on a constant-currency basis, Edwards Lifesciences raised its 2026 sales-growth outlook, also measured on a constant-currency basis, to about 11.5% from 10% to 11%. Sales for the quarter ended Sept. 30 totaled $1.7155 billion. The reported increase was 10.5%, while growth on a constant-currency comparison was 11.2%. Edwards released the third-quarter figures on Nov. 4. The revised adjusted earnings-per-share (EPS) outlook, a non-GAAP measure, is $2.97 to $3.05 per diluted share, compared with the former $2.95 to $3.05 range. The change raises the lower end by 2 cents, while the upper end is unchanged.
Source: TokenPost
